# Cannabis was just removed from the same category as heroin in the US The historic federal … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-was-just-removed-from-the-same-category-as-heroin-in-the-us-the-historic-federal/ > **Published:** 2026-07-11T17:09:48-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:04:11-04:00 > **Clinical Summary:** DEA rescheduling of cannabis from Schedule I opens the door to clinical trials. What this means for patient care and evidence-based practice. --- ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchSafetyMental HealthPainAnxietyNeurology Why This Matters This reclassification from Schedule I to Schedule III removes federal barriers that have severely limited [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on cannabis for decades, enabling rigorous trials that can establish safety and efficacy profiles for specific medical conditions. Clinicians will gain access to evidence-based dosing, formulations, and treatment protocols rather than relying on anecdotal reports, allowing for more informed discussions with patients about potential [therapeutic benefits](https://cedclinic.com/therapeutic-benefits-of-thc/) and risks. Patients may see faster development of FDA-approved cannabis-derived medications and clearer clinical guidance on appropriate use for conditions like [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), nausea, and seizure disorders. Clinical Summary The recent reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act represents a significant regulatory shift that will substantially reduce barriers to [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) in the United States. Previously, the Schedule I designation severely limited researchers’ ability to obtain cannabis for studies and imposed burdensome regulatory requirements that impeded investigation of cannabis’s therapeutic potential. This change is expected to facilitate more rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) examining cannabis efficacy for various conditions, including [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), nausea, epilepsy, and other indications where preliminary evidence suggests benefit. Clinicians can anticipate improved access to high-quality evidence about [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/) and efficacy, which will better inform prescribing decisions and patient counseling. Additionally, the reclassification may accelerate pharmaceutical development of cannabis-derived therapeutics and standardized formulations. For practicing clinicians, this regulatory change means that evidence-based guidance on cannabis use in clinical practice will likely become available more rapidly, allowing for more informed treatment discussions with patients seeking cannabis as a therapeutic option. Dr. Caplan’s Take “This rescheduling is administratively significant because it removes a genuine barrier to rigorous human research, but I want to be clear: easier access to study cannabis doesn’t mean we suddenly have answers about efficacy for specific conditions. We now have the opportunity to conduct the properly controlled trials we’ve lacked, and that’s where the real clinical evidence will come from.” Clinical Perspective 💊 The rescheduling of cannabis from Schedule I to Schedule III represents a meaningful shift in research accessibility that clinicians should monitor closely, as it will likely accelerate the generation of rigorous efficacy and safety data for specific indications. However, practitioners should remain cautious about interpreting emerging evidence, recognizing that decades of research constraints have created a substantial evidence gap compared to conventional pharmaceuticals, and that early studies may be subject to selection bias, small sample sizes, or industry influence. The practical implication for current clinical practice is that while cannabis may increasingly appear in patient discussions and future treatment guidelines, clinicians should continue advising patients that robust evidence for most indications remains limited, encourage reporting of any use during medication reconciliation given potential drug interactions, and stay informed about evolving state regulations that may affect legal prescribing options in their jurisdiction. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20was%20just%20removed%20from%20the%20same%20category%20as%20heroin%20in%20the%20US%20The%20historic%20federal%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68915)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68915)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20was%20just%20removed%20from%20the%20same%20category%20as%20heroin%20in%20the%20US%20The%20historic%20federal%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68915)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [How Cannabis Got Stigmatized: A Global History of Suppression, Politics & Healing](https://cedclinic.com/history-of-cannabis-oppression-and-stigma/) 📰 Source: [https://www.facebook.com/ScienceNaturePage/posts/cannabis-was-just-removed-from-the-same-category-as-heroin-in-the-us-the-histori/1575213517392845/](https://www.facebook.com/ScienceNaturePage/posts/cannabis-was-just-removed-from-the-same-category-as-heroin-in-the-us-the-histori/1575213517392845/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).